FibroGen
Yinan Zhang currently serves as the IT Compliance Manager at FibroGen, Inc. since June 2020, focusing on GxP and Sox IT compliance for Fibrogen China. Previously, from September 2017 to May 2020, Yinan held the position of Line Manager at NNIT, providing consultancy in the GxP area within the life sciences sector. Prior to that role, from February 2009 to September 2017, Yinan was employed by Novo Nordisk as a Senior PS IT QA, where responsibilities included designing and improving quality-related business processes, supporting compliance targets, and overseeing validation for various GxP IT systems. Yinan also worked as a Senior QA for computer system validation and facilities at Novo Nordisk, participating in the validation and release of automated systems in the filling plant. Yinan holds a bachelor's degree in Electronic Information Engineering from Tianjin University of Technology.
This person is not in any offices
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.